S.H. Hamilton

3.7k total citations · 2 hit papers
41 papers, 3.0k citations indexed

About

S.H. Hamilton is a scholar working on Psychiatry and Mental health, Pharmacology and Economics and Econometrics. According to data from OpenAlex, S.H. Hamilton has authored 41 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Psychiatry and Mental health, 19 papers in Pharmacology and 7 papers in Economics and Econometrics. Recurrent topics in S.H. Hamilton's work include Schizophrenia research and treatment (27 papers), Treatment of Major Depression (18 papers) and Bipolar Disorder and Treatment (9 papers). S.H. Hamilton is often cited by papers focused on Schizophrenia research and treatment (27 papers), Treatment of Major Depression (18 papers) and Bipolar Disorder and Treatment (9 papers). S.H. Hamilton collaborates with scholars based in United States, Ireland and United Kingdom. S.H. Hamilton's co-authors include Charles M. Beasley, Gary D. Tollefson, T.M. Sanger, W. Satterlee, P. Tran, Pierre V. Trân, Amy J. Kuntz, Scott W. Andersen, Janet H. Potvin and Dennis A. Revicki and has published in prestigious journals such as Biological Psychiatry, Annals of Oncology and Psychological Medicine.

In The Last Decade

S.H. Hamilton

39 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olanzapine versus Placebo and Haloperidol

1996 643 citations Charles M. Beasley, Gary D. Tollefson et al. Neuropsychopharmacology profile →
Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders

1997 567 citations Pierre V. Trân, S.H. Hamilton et al. Journal of Clinical Psychopharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S.H. Hamilton United States	18	2.4k	725	598	483	354	41	3.0k
Martina Hummer Austria	31	2.9k 1.2×	461 0.6×	686 1.1×	681 1.4×	180 0.5×	69	3.7k
Joseph Peuskens Belgium	37	3.4k 1.4×	676 0.9×	638 1.1×	697 1.4×	174 0.5×	147	4.6k
Donna A. Wirshing United States	28	2.4k 1.0×	379 0.5×	483 0.8×	653 1.4×	100 0.3×	50	3.4k
William C. Wirshing United States	31	2.8k 1.2×	426 0.6×	665 1.1×	824 1.7×	92 0.3×	90	3.9k
William M. Glazer United States	29	2.1k 0.9×	301 0.4×	450 0.8×	644 1.3×	155 0.4×	103	3.0k
Jean-Pierre Lindenmayer United States	29	2.9k 1.2×	424 0.6×	501 0.8×	840 1.7×	100 0.3×	43	4.0k
Stephan Heres Germany	28	3.2k 1.4×	508 0.7×	973 1.6×	1.1k 2.3×	345 1.0×	86	4.3k
Pierre V. Trân United States	17	1.5k 0.6×	616 0.8×	304 0.5×	297 0.6×	146 0.4×	28	1.9k
Daniel E. Casey United States	31	2.8k 1.2×	408 0.6×	312 0.5×	436 0.9×	139 0.4×	73	4.2k
Johannes Schneider‐Thoma Germany	28	2.1k 0.9×	497 0.7×	429 0.7×	530 1.1×	107 0.3×	63	2.9k

Countries citing papers authored by S.H. Hamilton

Since Specialization

Citations

This map shows the geographic impact of S.H. Hamilton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.H. Hamilton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.H. Hamilton more than expected).

Fields of papers citing papers by S.H. Hamilton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.H. Hamilton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.H. Hamilton. The network helps show where S.H. Hamilton may publish in the future.

Co-authorship network of co-authors of S.H. Hamilton

This figure shows the co-authorship network connecting the top 25 collaborators of S.H. Hamilton. A scholar is included among the top collaborators of S.H. Hamilton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.H. Hamilton. S.H. Hamilton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hamilton, S.H., et al.. (2024). Experiences of women with breast cancer disclosing cancer-related cognitive impairment symptoms to health professionals: a Systematic review and meta-synthesis. Journal of Psychosocial Oncology. 42(6). 888–908.

Oxlad, Melissa, et al.. (2024). Young males’ perspectives of gender-transformative health promotion programs: A systematic review and metasynthesis.. Psychology of Men & Masculinity. 26(3). 343–359.

Connolly, Roisín M., Petros Grivas, Edith P. Mitchell, et al.. (2020). 553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J. Annals of Oncology. 31. S479–S480. 2 indexed citations

Caldwell, Mary, et al.. (2015). Fecal Microbiota Transplantation in Patients With Cancer Undergoing Treatment. Clinical journal of oncology nursing. 19(1). 111–114. 7 indexed citations

Beasley, Charles M., Virginia K. Sutton, S.H. Hamilton, et al.. (2003). A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse. Journal of Clinical Psychopharmacology. 23(6). 582–594. 76 indexed citations

Beasley, Charles M., S.H. Hamilton, & Martín Dossenbach. (2000). Relapse prevention with olanzapine. Schizophrenia Research. 41(1). 196–197. 10 indexed citations

Hamilton, S.H., E.T. Edgell, Dennis A. Revicki, & Alan Breier. (2000). Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. International Clinical Psychopharmacology. 15(5). 245–255. 77 indexed citations

Hamilton, S.H., Dennis A. Revicki, E.T. Edgell, Laura A. Genduso, & Gary D. Tollefson. (1999). Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia. PharmacoEconomics. 15(5). 469–480. 82 indexed citations

Breier, Alan & S.H. Hamilton. (1999). Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia∗∗See accompanying Editorial, in this issue.. Biological Psychiatry. 45(4). 403–411. 97 indexed citations

10.

Revicki, Dennis A., Laura A. Genduso, S.H. Hamilton, Dara Ganoczy, & Charles M. Beasley. (1999). Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial. Quality of Life Research. 8(5). 417–426. 121 indexed citations

11.

Palmer, Cynthia S., Dennis A. Revicki, Laura A. Genduso, S.H. Hamilton, & Richard E. Brown. (1998). A cost-effectiveness clinical decision analysis model for schizophrenia.. PubMed. 4(3). 345–55. 66 indexed citations

12.

Hamilton, S.H., Alan Breier, & S.R. David. (1998). Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. European Neuropsychopharmacology. 8. S228–S228. 5 indexed citations

13.

Trân, Pierre V., S.H. Hamilton, Amy J. Kuntz, et al.. (1997). Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders. Journal of Clinical Psychopharmacology. 17(5). 407–418. 567 indexed citations breakdown →

14.

Beasley, Charles M., S.H. Hamilton, A.M. Crawford, et al.. (1997). Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology. 7(2). 125–137. 245 indexed citations

15.

Hamilton, S.H., et al.. (1997). Fluoxetine in Medically Stable, Depressed Geriatric Patients. Journal of Clinical Psychopharmacology. 17(5). 365–369. 23 indexed citations

16.

Beasley, Charles M., T.M. Sanger, W. Satterlee, et al.. (1996). Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 124(1-2). 159–167. 320 indexed citations

17.

Beasley, Charles M., Gary D. Tollefson, P. Tran, et al.. (1996). Olanzapine versus Placebo and Haloperidol. Neuropsychopharmacology. 14(2). 111–123. 643 indexed citations breakdown →

18.

Small, Gary W., S.H. Hamilton, Alexander Bystritsky, Barnett S. Meyers, & Charles B. Nemeroff. (1995). Clinical Response Predictors in a Double-Blind, Placebo-Controlled Trial of Fluoxetine for Geriatric Major Depression. International Psychogeriatrics. 7. 41–53. 30 indexed citations

19.

Hamilton, S.H., Marc Hertzman, Barnett S. Meyers, et al.. (1995). Predicting Response to Fluoxetine in Geriatric Patients With Major Depression. Journal of Clinical Psychopharmacology. 15(6). 421–427. 34 indexed citations

20.

Goldstein, D., Alvin H. Rampey, Paul Roback, et al.. (1995). Efficacy and Safety of Long‐Term Fluoxetine Treatment of Obesity ‐ Maximizing Success. Obesity Research. 3(S4). 481S–490S. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact